Vfend(voriconazole)
Vfend, Voriconazole (voriconazole) is a small molecule pharmaceutical. Voriconazole was first approved as Vfend on 2002-03-19. It is used to treat aspergillosis, candidiasis, fusariosis, and mycoses in the USA. It has been approved in Europe to treat aspergillosis, bacterial infections and mycoses, candidiasis, and mycoses.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Vfend (generic drugs available since 2010-04-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Voriconazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VFEND | CV Sciences | N-021266 RX | 2002-05-24 | 2 products, RLD, RS |
| VFEND | CV Sciences | N-021267 RX | 2002-05-24 | 1 products, RLD, RS |
| VFEND | CV Sciences | N-021630 RX | 2003-12-19 | 1 products, RLD, RS |
| VORICONAZOLE | Xellia | N-208562 RX | 2017-03-09 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vfend | New Drug Application | 2024-09-06 |
| vfender | OTC monograph not final | 2020-05-30 |
| vfender hand sanitizer gel | OTC monograph not final | 2020-09-01 |
| voriconazole | ANDA | 2024-09-18 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3465 | Injection, voriconazole, 10 mg |
Clinical
Clinical Trials
190 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | 8 | 9 | 18 | 10 | 21 | 65 |
| Aspergillosis | D001228 | EFO_0007157 | B44 | 4 | 11 | 14 | 7 | 7 | 40 |
| Infections | D007239 | EFO_0000544 | — | 3 | 6 | 7 | 3 | 9 | 27 |
| Invasive fungal infections | D000072742 | — | — | — | 3 | 5 | 4 | 9 | 21 |
| Invasive pulmonary aspergillosis | D055744 | — | B44.0 | 1 | 3 | 4 | 2 | 6 | 16 |
| Healthy volunteers/patients | — | — | — | 12 | — | — | 3 | 1 | 16 |
| Communicable diseases | D003141 | — | — | 2 | 3 | 3 | 2 | 4 | 14 |
| Candidiasis | D002177 | — | B37 | 2 | 2 | 5 | 3 | 1 | 13 |
| Pulmonary aspergillosis | D055732 | EFO_1001834 | — | 1 | 4 | 5 | 1 | 3 | 12 |
| Hematologic neoplasms | D019337 | — | — | 2 | 2 | 2 | 1 | 2 | 8 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 5 | 8 | 4 | — | 3 | 16 |
| Neoplasms | D009369 | — | C80 | 3 | 7 | 1 | — | 3 | 13 |
| Myeloid leukemia | D007951 | — | C92 | 5 | 9 | 1 | — | 1 | 11 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 8 | 1 | — | 1 | 10 |
| Keratitis | D007634 | HP_0000491 | H16 | 2 | 2 | 2 | — | 3 | 7 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | 1 | — | 1 | 5 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 3 | — | 1 | — | 1 | 5 |
| Corneal ulcer | D003320 | — | H16.0 | 1 | — | 3 | — | 1 | 5 |
| Neutropenia | D009503 | — | D70 | 1 | 2 | 1 | — | 2 | 5 |
| Syndrome | D013577 | — | — | 1 | 2 | 1 | — | 1 | 4 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 3 | — | — | 1 | 4 |
| Preleukemia | D011289 | — | — | 1 | 3 | — | — | — | 3 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 2 | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 1 | 1 | — | — | 1 | 3 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 1 | — | — | 1 | 3 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | 1 | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 2 | 2 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | 1 | 2 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 2 | — | — | — | 1 | 3 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | 1 | 2 |
| Stem cell transplantation | D033581 | — | — | 2 | — | — | — | — | 2 |
| Hiv-1 | D015497 | — | — | 1 | — | — | — | — | 1 |
| Phototoxic dermatitis | D017484 | — | — | 1 | — | — | — | — | 1 |
| Bacterial infections | D001424 | — | A49 | 1 | — | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
| Anesthesia | D000758 | — | — | 1 | — | — | — | — | 1 |
| Meningitis | D008581 | HP_0001287 | G03 | 1 | — | — | — | — | 1 |
| Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 4 | 4 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 2 | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 2 | 2 |
| Bone marrow transplantation | D016026 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
Show 38 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Voriconazole |
| INN | voriconazole |
| Description | Voriconazole is a triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. It has a role as a P450 inhibitor. It is a member of pyrimidines, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F |
Identifiers
| PDB | — |
| CAS-ID | 137234-62-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL638 |
| ChEBI ID | 10023 |
| PubChem CID | 71616 |
| DrugBank | DB00582 |
| UNII ID | JFU09I87TR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Vfend – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Voriconazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,330 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,752 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use